COST

1,037.71

+0.49%↑

80.58

+0.24%↑

142.88

+0.45%↑

191.61

+1.38%↑

PEP

148.49

-0.61%↓

COST

1,037.71

+0.49%↑

80.58

+0.24%↑

142.88

+0.45%↑

191.61

+1.38%↑

PEP

148.49

-0.61%↓

COST

1,037.71

+0.49%↑

80.58

+0.24%↑

142.88

+0.45%↑

191.61

+1.38%↑

PEP

148.49

-0.61%↓

COST

1,037.71

+0.49%↑

80.58

+0.24%↑

142.88

+0.45%↑

191.61

+1.38%↑

PEP

148.49

-0.61%↓

COST

1,037.71

+0.49%↑

80.58

+0.24%↑

142.88

+0.45%↑

191.61

+1.38%↑

PEP

148.49

-0.61%↓

Strona główna・Stock List・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Open

SectorConsumer defensive

4.62 1.09

Buy Sell

Overview

Share price change

24h

Current

Min

4.38

Max

4.66

Key metrics
By Trading Economics
Income	3.9M -6M
Sales	-5.3M 31M
Profit margin	-19.435
Employees	382

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+48.22% upside

Market Stats
By TradingEconomics
Market Cap	-92M 149M
Previous open	3.53
Previous close	4.62

News Sentiment

By Acuity

50%

67 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 maj 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 maj 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 maj 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 maj 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 maj 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 maj 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 maj 2026, 23:02 UTC

Market Talk

Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 maj 2026, 22:59 UTC

Market Talk

Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 maj 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 maj 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 maj 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 maj 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 maj 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 maj 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 maj 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 maj 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 maj 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Price Target

By TipRanks

48.22% upside

12 Months Forecast

Average 6.67 USD 48.22%

High 9 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forLifecore Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Lifecore Biomedical Inc - Dist in the past 3 months.

Sentiment

By Acuity

67 / 131 Ranking in Consumer defensive

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.